Kolon TissueGene Inc是一家生物制药公司。该公司开发基于细胞的疗法来治疗骨关节炎、骨科疾病和其他退行性疾病。该公司的平台技术包括同种异体原代细胞与转基因细胞在一个可注射治疗剂量中的组合。TG-C是该公司的主要候选产品,已开发用于治疗膝关节骨关节炎(OA),已在美国完成II期试验。TG-C是一种同种异体、供体细胞和基因疗法,涉及原代人软骨细胞(该软骨细胞)和转导以表达治疗性生长因子TGF-ß1的人细胞,通过一次关节内注射将其递送至膝关节。它的产品线属于骨关节炎、肌肉骨骼系统疾病和兽医药等类别。该公司还在开发肌肉骨骼系统疾病的治疗方法,例如类风湿性关节炎、半月板和椎间盘。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Moon-Jong Noh | CEO, President & Director | 2025 | 58 |
| Seng-Ho Jeon | CEO & Director | 2025 | 56 |
| Jung In Kim | CFO & Director | 2022 | 48 |
| Young J. Kim | Statutory Auditor & Director | 2021 | 64 |
| Peter Shin | Member of Business Advisory Board | - | - |
| Terry L. Lierman | Member of Business Advisory Board | - | 78 |
| Michael A. Mont | Member of Clinical Advisory Board | - | - |
| Javad Parvizi | Member of Clinical Advisory Board | - | - |
| David Hunter | Member of Scientific Advisory Board | 2016 | - |
| Philip G. Conaghan | Member of Scientific Advisory Board | 2017 | - |
| Ali Mobasheri | Member of the Scientific Advisory Board | 2020 | - |
| SunJoo Lee | Independent Outside Director | 2023 | 59 |
| Jeon Seungho | Director | 2025 | 51 |